𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Long-term survival and DNA ploidy in advanced epithelial ovarian cancer

✍ Scribed by Resnik, Ephraim; Trujillo, Yollanda P.; Taxy, Jerome B.


Publisher
John Wiley and Sons
Year
1997
Tongue
English
Weight
156 KB
Volume
64
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

✦ Synopsis


Background and objectives:

The relationship of the tumor dna content to survival of patients with advanced epithelial cancer has not yet been clarified. a large amount of contradictory data exists in the literature. this study analyzes the putative relationship between ploidy and advanced ovarian carcinoma.

Methods:

A retrospective analysis of tumor ploidy, dna index, and the s-phase fraction from 35 patients with nonborderline epithelial ovarian carcinomas was determined by flow cytometry of paraffin-embedded tissue. all patients had figo stage iii or iv disease. those patients who survived > 5 years were assigned to group a (10 patients). group b consisted of 25 age-matched subjects who succumbed to their disease within 5 years of diagnosis.

Results:

Group a had not reached a median overall survival with a median follow-up of 114 months (range 67-226), whereas group b had a median overall survival of 17 months (range 1-48). two of the patients in group a and all of the patients in group b had died of the disease. the two groups were similar in age, histologic type, and treatment. in group a, three patients had grade 1 tumors, in contrast to group b where all the patients had either grade 2 or 3 disease (p = 0.018). however, the distribution of aneuploidy was similar in both groups. also, the dna indices were similar: 1.40 +/- 0.42 in group a, and 1.36 +/- 0.44 in group b. the median s-phase fraction was 14% (range 3-23%) in group a, and 15% (range 2-23%) in group b. the grade and type of tumor were not related to the ploidy or the dna index. there was no significant correlation between ploidy or the dna index and survival.

Conclusion:

This study suggests that the dna content of tumor as measured by flow cytometry is not a predictor of long-term survival in ovarian cancer patients with advanced disease.


πŸ“œ SIMILAR VOLUMES


DNA ploidy in colorectal cancer, heterog
✍ Henrik L. Flyger; JΓΈrgen K. Larsen; Hans J. Nielsen; Ib J. Christensen πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 189 KB πŸ‘ 2 views

Flow cytometry was used to study the incidence of aneuploidy and to determine the significance of multiple sampling from colorectal tumors. DNA ploidy pattern has been proposed as a supplementary prognostic marker, but discrepancies in findings are major. DNA clonal heterogeneity, defined as two or

Ifosfamide, paclitaxel and cisplatin fir
✍ Christos A. Papadimitriou; Charalambos Kouroussis; Lia A. Moulopoulos; Georgios πŸ“‚ Article πŸ“… 2001 πŸ› John Wiley and Sons 🌐 English βš– 97 KB

## BACKGROUND. The combination of paclitaxel with a platinum analogue is the preferred chemotherapy regimen in the treatment of advanced epithelial ovarian carcinoma. The alkylating agent ifosfamide has shown activity in refractory or recurrent ovarian cancer. We conducted a Phase II study with th

Plasminogen activator inhibitor-1 is an
✍ Setsuko K. Chambers; Christina M. Ivins; Maria L. Carcangiu πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 French βš– 103 KB πŸ‘ 2 views

High levels of plasminogen activator inhibitor-1 (PAI-1) in tissue extracts have been associated with poor prognosis in many epithelial cancers. Ovarian cancers contain a higher concentration of PAI-1 than benign ovarian tumors or normal ovaries. Reports, however, on the prognostic value of PAI-1 co